Paxil Generalized Anxiety Relapse Prevention Data To Be Presented At APA
Executive Summary
GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.
You may also be interested in...
GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.